In silico tool for identification of colorectal cancer from cell-free DNA biomarkers

TL;DR

This study develops an in silico diagnostic tool using machine learning on cfDNA methylation data to accurately detect colorectal cancer noninvasively, with promising performance metrics.

Contribution

The paper introduces a novel combination of methylation biomarker selection and machine learning models for CRC detection from cfDNA, achieving high accuracy.

Findings

Best model (MLP) achieved AUROC of 0.89

Selected 25 CpG features for optimal performance

Deep learning model achieved AUROC of 0.78

Abstract

Colorectal cancer remains a major global health concern, with early detection being pivotal for improving patient outcomes. In this study, we leveraged high throughput methylation profiling of cellfree DNA to identify and validate diagnostic biomarkers for CRC. The GSE124600 study data were downloaded from the Gene Expression Omnibus, as the discovery cohort, comprising 142 CRC and 132 normal cfDNA methylation profiles obtained via MCTA seq. After preprocessing and filtering, 97,863 CpG sites were retained for further analysis. Differential methylation analysis using statistical tests identified 30,791 CpG sites as significantly altered in CRC samples, where p is less than 0.05. Univariate scoring enabled the selection of top ranking features, which were further refined using multiple feature selection algorithms, including Recursive Feature Elimination, Sequential Feature Selection, and SVC L1. Various machine learning models such as Logistic Regression, Support Vector Machines, Random Forest, and Multi layer Perceptron were trained and tested using independent validation datasets. The best performance was achieved with an MLP model trained on 25 features selected by RFE, reaching an AUROC of 0.89 and MCC of 0.78 on validation data. Additionally, a deep learning based convolutional neural network achieved an AUROC of 0.78. Functional annotation of the most predictive CpG sites identified several genes involved in key cellular processes, some of which were validated for differential expression in CRC using the GEPIA2 platform. Our study highlights the potential of cfDNA methylation markers combined with ML and DL models for noninvasive and accurate CRC detection, paving the way for clinically relevant diagnostic tools.